The Technical Analyst
Inhibrx, Inc. [INBX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Inhibrx, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.32% $34.24
America/New_York / 24 apr 2024 @ 15:02
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 622.72 mill |
| EPS: | -5.12 |
| P/E: | -6.69 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 47.39 mill |
| Avg Daily Volume: | 0.523 mill |
| RATING 2024-04-23 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.69 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.14x |
| Company: PE -6.69 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.312 (-96.17%) $-32.93 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 33.67 - 34.87 ( +/- 1.74%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-26 | Deck Kelly | Sell | 625 | Stock Option (right to buy) |
| 2024-03-26 | Deck Kelly | Sell | 396 | Stock Option (right to buy) |
| 2024-03-26 | Deck Kelly | Sell | 1 459 | Stock Option (right to buy) |
| 2024-03-26 | Deck Kelly | Sell | 416 | Stock Option (right to buy) |
| 2024-03-20 | Deck Kelly | Sell | 16 777 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 56.11 |
| Last 100 transactions |
| Buy: 3 248 725 | Sell: 1 114 859 |
Forecast:
16:00 - $34.24
Live Trading Signals (every 1 min)
Forecast
1: 15:11 - $34.22
Forecast 2: 16:00 - $34.24
Forecast 3: 16:00 - $34.24
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $34.24 (0.32% ) |
| Volume | 0.102 mill |
| Avg. Vol. | 0.523 mill |
| % of Avg. Vol | 19.48 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For INBX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $37.41 | N/A | Active |
|---|
INBX
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Latest Press Releases
2024-02-28 09:15:00 - Press Release
Inhibrx Reports Fourth Quarter And Fiscal Year 2023 Financial Results
San diego, feb. 28, 2024 /prnewswire/ -- inhibrx, inc. (nasdaq: inbx) ("inhibrx" or the "company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023. key highlights sale of inbrx-101 to sanofi: in january 2024, the company announced that it entered into a definitive agreement with aventis, inc. ("aventis"), a subsidiary of sanofi, whereby sanofi will indirectly acquire, through aventis, all of the assets and liabilities associated with inbrx-101 ("the merger").
2024-02-10 10:46:00 - Press Release
Inhibrx Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Inhibrx, Inc. - Inbx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of inhibrx, inc. (nasdaqgm: inbx) to sanofi (nasdaqgs: sny). under the terms of the proposed transaction, shareholders of inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will.
2024-01-23 12:03:00 - Press Release
Unitholder Alert: Ademi Llp Investigates Whether Inhibrx, Inc. Has Obtained A Fair Price In Its Transaction With Sanofi
Milwaukee , jan. 23, 2024 /prnewswire/ -- ademi llp is investigating inhibrx (nasdaq: inbx) in connection with its transaction with sanofi. click here to learn how to join https://www.ademilaw.com/case/inhibrx-inc or call guri ademi toll-free at 866-264-3995.
2024-01-23 09:33:00 - Press Release
Inbx Stock Alert: Halper Sadeh Llc Is Investigating Whether The Sale Of Inhibrx, Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the sale of inhibrx, inc. (nasdaq: inbx) to sanofi is fair to inhibrx shareholders. under the terms of the proposed transaction, for each inhibrx share, inhibrx shareholders will receive $30.00 in cash, a contingent value right of $5.00, conditioned upon the achievement of a regulatory milestone, and 0.25 shares of a new publicly traded company that will retain inhibrx's non-inbrx-101 assets. halp.
2024-01-23 01:00:00 - Press Release
Inhibrx Announces Sale Of Inbrx-101 To Sanofi For An Aggregate Value Of Up To $2.2b
Inhibrx, inc. shareholders will receive per share consideration of $30 per share in cash, a cvr equal to $5, plus 0.25 shares in new inhibrx, a new publicly traded company that retains all non-101 assets of inhibrx, inc. sanofi to pay off inhibrx's outstanding debt balance and capitalize new inhibrx with $200 million in cash san diego , jan. 23, 2024 /prnewswire/ -- inhibrx, inc. (nasdaq: inbx) ("inhibrx," or the "company") and sanofi (nasdaq: sny) ("sanofi") today announced that the companies have entered into a definitive agreement under which aventis inc., a pennsylvania corporation (a subsidiary of sanofi) will acquire all the assets and liabilities associated with inbrx-101, an optimized, recombinant alpha-1 antitrypsin ("aat") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("aatd")...
Latest News
2024-02-28 11:25:28 - Zacks Investment Research
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.73 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.95 per share a year ago.
2024-01-24 07:01:04 - Zacks Investment Research
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2024-01-23 15:31:04 - Zacks Investment Research
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
2024-01-23 11:45:37 - Investopedia
Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline
Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to treat rare diseases.
2023-09-01 16:26:33 - GuruFocus
Andreas Halvorsen's Firm Ups Inhibrx Stake
Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% following a private placement financing agreement.
2023-08-17 16:41:26 - Seeking Alpha
Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much
INBX is researching a breakthrough for Alpha-1 Antitrypsin deficiency and has received regulatory support for its INBRX-101 pipeline. The AATD treatment market is expected to experience robust growth in the coming years. INBRX-101 has received Fast Track designation from the FDA for the treatment of emphysema.
2023-06-27 09:40:00 - Market Watch
Theft in open court: How a fight over lifesaving drugs led to charges of brazen industrial espionage
A Chinese developer of cutting-edge cancer drugs has accused a chief competitor of stealing its trade secrets by posing as an expert witness in an arbitration hearing as a way of surreptitiously getting a look at its proprietary research.
2023-05-08 19:45:45 - Zacks Investment Research
Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates
Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.80 per share a year ago.
2023-05-04 03:49:05 - Zacks Investment Research
Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2023-03-06 18:49:24 - Zacks Investment Research
Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -18.75% and 8.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?